Insider Transactions in Q4 2020 at Arcutis Biotherapeutics, Inc. (ARQT)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.67%
|
$0
$0.58 P/Share
|
|
Dec 14
2020
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
3,750
-3.8%
|
$112,500
$30.0 P/Share
|
|
Dec 14
2020
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-5.62%
|
$45,000
$30.0 P/Share
|
|
Dec 14
2020
|
John W Smither Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.32%
|
$1,500
$1.68 P/Share
|
|
Dec 14
2020
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-5.65%
|
$450,000
$30.0 P/Share
|
|
Dec 01
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-0.4%
|
$57,200
$26.28 P/Share
|
|
Dec 01
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.6%
|
$2,200
$1.68 P/Share
|
|
Nov 12
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.67%
|
$0
$0.58 P/Share
|
|
Nov 02
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-1.22%
|
$39,600
$18.27 P/Share
|
|
Nov 02
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.6%
|
$2,200
$1.68 P/Share
|
|
Oct 26
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,668
+10.88%
|
$16,008
$6.52 P/Share
|
|
Oct 22
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,695
+12.31%
|
$16,170
$6.52 P/Share
|
|
Oct 15
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.68%
|
$0
$0.58 P/Share
|
|
Oct 15
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+31.25%
|
$45,000
$6.52 P/Share
|
|
Oct 02
2020
|
Jonathan Silverstein Director |
BUY
Open market or private purchase
|
Indirect |
496,000
+14.59%
|
$12,400,000
$25.0 P/Share
|
|
Oct 02
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
496,000
+14.59%
|
$12,400,000
$25.0 P/Share
|
|
Oct 01
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-0.61%
|
$57,200
$26.68 P/Share
|
|
Oct 01
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.61%
|
$2,200
$1.68 P/Share
|